Parabilis Medicines (Nasdaq: PBLS) sold shares to Regeneron at 90% of the $20.00 IPO price under a Stock Purchase Agreement dated June 9, 2026. The placement closed June 11, 2026.
Parabilis Medicines priced 33,500,000 shares at $20.00 each, and Regeneron agreed to buy $75.0 million of stock at 90% of the IPO price, as the company's net loss reached $145,889 thousand in 2025.
Parabilis Medicines filed its IPO registration on May 19, 2026, with a $75.0 million Regeneron private placement tied to a collaboration, while its net loss grew to $145,889 thousand in 2025.
Questions about Parabilis Medicines
When did Parabilis Medicines go public?
Our latest story on this, dated Jun 11, 2026: "Parabilis Medicines closes private placement of 4,166,666 shares to Regeneron alongside IPO". The story links the filing or release it is based on. Read the story.
Has Parabilis Medicines raised money recently?
Our latest story on this, dated Jun 11, 2026: "Parabilis Medicines closes private placement of 4,166,666 shares to Regeneron alongside IPO". The story links the filing or release it is based on. Read the story.
Is Parabilis Medicines involved in a merger or acquisition?
Our latest story on this, dated May 19, 2026: "Parabilis Medicines files for IPO; Regeneron agrees to buy about $75.0 million of stock". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Parabilis Medicines?
Parabilis Medicines, Inc. trades under the ticker PBLS on NASDAQ.
Where is Parabilis Medicines listed?
Parabilis Medicines, Inc. is listed on NASDAQ.
What is the SEC CIK of Parabilis Medicines?
The SEC Central Index Key (CIK) for Parabilis Medicines, Inc. is 1657677. Its filings are on SEC EDGAR.
Which country or territory is Parabilis Medicines listed under?
Our directory records Parabilis Medicines, Inc. under United States.
What does Parabilis Medicines do?
Our directory classifies Parabilis Medicines, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Parabilis Medicines?
The ISIN recorded for Parabilis Medicines, Inc. is US6989551014.
Does aibio.space cover Parabilis Medicines?
aibio.space lists Parabilis Medicines, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Parabilis Medicines incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest Parabilis Medicines (PBLS) stock news?
Our latest story on Parabilis Medicines, dated Jun 11, 2026: "Parabilis Medicines closes private placement of 4,166,666 shares to Regeneron alongside IPO". Parabilis Medicines (Nasdaq: PBLS) sold shares to Regeneron at 90% of the $20.00 IPO price under a Stock Purchase Agreement dated June 9, 2026. The placement closed June 11, 2026. Source.
How long will Parabilis Medicines's cash last?
From our story of Jun 10, 2026: The company says the net proceeds, together with existing cash and that upfront payment, will be sufficient to fund operations into the second half of 2029, but it adds that its operating plan may change and it may need more money sooner. Source.
Is Parabilis Medicines a smaller reporting company?
SEC records list Parabilis Medicines, Inc.'s filer category as: <br>Emerging growth company.
Where is Parabilis Medicines headquartered?
SEC records list its business address as 30 ACORN PARK DRIVE, CAMBRIDGE, MA, 02140.
Investor discussion: Parabilis Medicines
Members talk about Parabilis Medicines (PBLS). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Parabilis Medicines, newest first. Each line links the filing it comes from.
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:PBLS on TradingView.
SEC filings and registration
SEC name
Parabilis Medicines, Inc.
CIK
1657677
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
PBLS (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
30 ACORN PARK DRIVE, CAMBRIDGE, MA, 02140
Phone
617-945-9510
Former names
FOG PHARMACEUTICALS, INC.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Parabilis Medicines, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PBLS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio